FLT3 and acute myeloid leukemia: This study involved a comprehensive clinical, genomic, and transcriptomic evaluation of FLT3 to elucidate its variations and their pathological impacts in pediatric ALL and AML, thereby informing the use of FLT3 inhibitors.